Mark R. Fielden - Concepedia

Author

Mark R. Fielden

Also Known As

M Fielden, M R Fielden, M. Fielden, M. R. Fielden, M.R Fielden, Mark Fielden, Mark R Fielden, Mark R. Fielden, Minjun Chen

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Amgen (United States)Michigan State University La Roche College Western University Texas A&M University

About

Mark R. Fielden is an author at Amgen (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	1.5K
2	Public Health	5	5	263
3	Natural Sciences	4	4	87
4	Engineering	3	3	533
5	Health Sciences	1	1	38

Mark R. Fielden

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action Brigitte Ganter, Stuart Tugendreich, Cecelia I. Pearson, Journal of Biotechnology Drug TargetEngineeringPredictive ToxicologyBiochemistryDrug Candidate Selection	2005	286
Induction of Cyp1a1 Is a Nonspecific Biomarker of Aryl Hydrocarbon Receptor Activation: Results of Large Scale Screening of Pharmaceuticals and Toxicants in Vivo and in Vitro Wenyue Hu, Claudio Sorrentino, Michael S. Denison, Molecular Pharmacology	2007	217
A Gene Expression Biomarker Provides Early Prediction and Mechanistic Assessment of Hepatic Tumor Induction by Nongenotoxic Chemicals Mark R. Fielden, Richard Brennan, Jeremy Gollub Toxicological Sciences Signature ProfileEngineeringPathologyNongenotoxic ChemicalsTumor Biology	2007	206
Comparative analysis of dioxin response elements in human, mouse and rat genomic sequences Yanni Sun, Darrell R. Boverhof, Lyle D. Burgoon, Nucleic Acids Research	2004	205
Examination of the estrogenicity of 2,4,6,2',6'-pentachlorobiphenyl (PCB 104), its hydroxylated metabolite 2,4,6,2',6'-pentachloro-4-biphenylol (HO-PCB 104), and a further chlorinated derivative, 2,4,6,2',4',6'-hexachlorobiphenyl (PCB 155). Mark R. Fielden, I Chen, Brock Chittim, Environmental Health Perspectives Endocrine DisruptorsBiochemistryPcb 155MedicineHormonal Receptor	1997	114
Validation of putative genomic biomarkers of nephrotoxicity in rats Er‐jia Wang, Ronald D. Snyder, Mark R. Fielden, Toxicology Renal FunctionRenal InflammationPathologyPutative Genomic BiomarkersMedicine	2008	111
Direct quantification of in vivo mutagenesis and carcinogenesis using duplex sequencing Charles C. Valentine, Robert R. Young, Mark R. Fielden, Proceedings of the National Academy of Sciences	2020	107
A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity Mark R. Fielden, Barrett P. Eynon, Georges Natsoulis, Toxicologic Pathology Gene SignatureTubular DegenerationRenal PathologyRenal InflammationPathology	2005	106
The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them Martyn T. Smith, Kathryn Z. Guyton, Nicole Kleinstreuer, Cancer Epidemiology Biomarkers & Prevention	2020	101
Interlaboratory Evaluation of Genomic Signatures for Predicting Carcinogenicity in the Rat Mark R. Fielden, Alex Nie, Michael McMillian, Toxicological Sciences	2008	92

Page 1